There have been a number of randomized controlled trials (RCTs) showing that insulin aspart leads to improved glycemic control without increasing the risk of hypoglycemia. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Although RCTs are of great value, they may not be fully representative of the general, heterogeneous patient population with complex chronic diseases, due to patient selection criteria. It has been proved that observational studies, which do not require controlled conditions and restrictive inclusion and exclusion criteria, are useful in validating clinical trial data on adverse events and efficiency of treatment in a large number of diverse patients, in the actual clinical practice. [31] [32] [33] Because patients with type 1 and some patients with type 2 diabetes use mealtime insulin every day, there is a need for an observational study to assess how glycemic control has been affected in routine clinical practice, which may complement data from RCTs and support evidence-based medicine. That is why we considered it important to evaluate the safety and efficacy of insulin aspart as mealtime insulin added to different basal insulin preparations in real clinical setting.
PAtIEnts And mEthods study design It was an open-label, nonrandomized, noninterventional, 13-week observational study involving 2388 patients with type 1 or type 2 diabetes and conducted in the setting of routine clinical practice. Patients were recruited from primary and secondary care settings and 1000 researchers were involved in data collection. The study was conducted between November 2006 and April 2007. Physicians made decisions about the dosage and duration of insulin therapy as well as the use of any other medications in individual cases.
The aim of the study was to evaluate the incidence rate of major hypoglycemic episodes in patients with any type of diabetes treated with insulin aspart in basal-bolus regimen in normal clinical conditions. The effectiveness of insulin aspart was considered a secondary endpoint.
Because it was an observational study, the decision to administer insulin aspart to a patient was made prior to inclusion in the study. In other words, whether a patient received insulin did not depend on whether he or she was included in the study; therefore, there was no need to obtain informed consent from patients or the approval of an ethics committee. study population Any patient with type 1 or 2 diabetes was eligible for the study if a physician decided to start intensive insulin therapy (basal--bolus regimen) with insulin aspart (Novo Rapid®, Novo Nordisk AS, Denmark) in addition to basal insulin therapy with neutral protamine Hagedor (NPH) insulin (Insulatard®, Novo Nordisk AS, Denmark) or long-acting insulin analogue detemir (Levemir®, Novo Nordisk AS, Denmark). There were no limitations concerning previous diabetes treatment; insulin aspart had to be started not earlier than 14 days before inclusion in hemo globin A 1c (HbA 1c ) levels of <7%, ≤6.5%, and ≤6.5%, respectively. 1-7 The Polish Diabetes Society recommends HbA 1c values <7% in patients with type 2 diabetes and <6.5% in patients with type 1 or newly diagnosed type 2 diabetes.
8 Patients with type 1 diabetes are dependent on exogenous insulin replacement therapy due to absolute insulin deficiency from the onset of the disease. Patients with type 2 diabetes may be initially treated mainly by lifestyle inter ventions alone, but due to the natural history of type 2 diabetes characterized by progressive loss of β-cell function, they will later require numerous pharmacological agents to maintain glycemic control, and eventually many patients will need insulin treatment. 9,10 Unfortunately, insulin therapy is underutilized in this most common type of diabetes. 11 Despite substantial literature data supporting the benefits of glucose lowering, mean HbA 1c levels are still high in this patient group.
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For many years, pharmacokinetic limitations of conventional insulin made treatment goals difficult to achieve, and intensive regimens often resulted in frequent hypoglycemia and weight gain. 1,3 Optimal meta bolic control requires treatment that mimics the physio logical basal and prandial insulin secretion of healthy individuals as closely as possible. 13 Because absorption time of human insulin is short and poorly reproductible, postprandial glucose (PPG) excursions are difficult to reduce. It is particularly important because PPG correlates more closely with the progression of cardiovascular disease than with either fasting glucose or HbA 1c levels.
14 -16 Modification of the insulin molecule with recombinant DNA technology led to synthesis of insulin analogues characterized by more physio logic time-action profiles. 17 Rapid-acting insulin analogues, such as insulin aspart, are chemically engineered variants of human insulin that were developed to match mealtime physio logical insulin secretion more closely. As an alternative to regular human insulin, insulin aspart injected before meals is more rapidly absorbed, has faster onset and shorter duration of action, as well as higher peak concentrations, mimicking the postprandial spike. A rapid-acting insulin analogue allows patients to "inject-and-eat", or even inject after meals, with no need for a 30-minute injection-meal inter val necessary in the case of short-acting human insulin.
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Of note, outcome measures of the studies assessing new insulin therapies and regimens evaluate not only near-normalization of blood glucose but also reduction of hypoglycemia risk. Evaluation of hypoglycemia is particularly important because it is common in insulin-treated diabetes and remains the major barrier for optimal glycemic control. What is even more important according to the recent data is that intensive glycemic control, which targets HbA 1c <6%, may be associated with worse clinical outcomes compared with standard glycemic control.
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an episode with either symptoms of hypoglycemia with blood glucose measurement <3.1 mmol/l that was self-treated by a patient, or any asymptomatic blood glucose measurement <3.1 mmol/l. Nocturnal hypoglycemia was defined as a symptomatic hypoglycemic episode occurring during sleep, between the evening insulin injection and morning wake up. Data concerning hypoglycemia was obtained mainly from patient diaries. If a diary was not available, the data was based on patient recollection obtained during medical inter view and a physician decided about its credibility.
statistical analysis The sample size was based on the primary objective of the study, namely evaluation of the incidence of major hypoglycemia reported as a serious adverse drug reaction. A sample of 4000 patients was needed to detect the incidence of serious adverse drug reactions of at least 0.025% with probability of at least 95%. It means that a total of 4000 patients were required to detect at least 1 serious adverse drug reaction occurring in 25 of 100,000 patients with 95% probability. To provide at least 4000 individuals for the final statistical analysis, we had to recruit 5000 patients given the fact that some patients might withdraw from the study and be lost to follow-up. Descriptive statistics were used to present baseline data from the full analysis set (FAS). Continuous variables were presented using descriptive statistics (mean, standard deviation [SD]). For categorical variables frequencies were computed (n,%). The primary endpoint (major hypoglycemia) was presented as a number of events and a number and proportion of patients suffering from a major hypoglycemic event. The total incidence of major hypoglycemia was summarized for 1 patient count-up and presented concomitantly.
For comparisons between the baseline and final visits, the paired t-test for normally distributed variables and the Wilcoxon's matched-pairs signed rank test for nonnormally distributed variables were used. The Shapiro-Wilk W test was used to verify normality assumptions. The main outcome variable was the incidence of major hypoglycemia events during a 13-week treatment with insulin aspart. Other outcome variables were secondary endpoints, i.e., safety and effectiveness. The incidence rate of severe hypoglycemia was calculated by dividing the total number of severe hypoglycemic events by the total number of patients. The differences in intensity of hypoglycemic events between the baseline and final visits were presented as incidence rate ratios (IRRs) and assessed using the general estimating equation for the Poisson panel data. IRR = 1 indicates that the intensity of hypoglycemic events did not differ between the 2 visits. IRR <1 when compared with the baseline visit indicates that the intensity of hypoglycemic events at the final visit was lower, and IRR >1 indicates that it was higher. Patients included in the FAS took part in the final study visit and had at least the study. In order to minimize selection bias, patients were enrolled on consecutive basis, until the quota of 5 patients for each participating physician was reached.
Patients were excluded from the study if they were unable to follow the protocol requirements such as assessment at the final visit, had hypersensitivity to insulin aspart or any of the excipients, or were included to the study previously. The decision to discontinue insulin aspart was at the discretion of individual physicians and was based on clinical evaluation of the patient's condition.
We recruited 5000 eligible patients; 2388 individuals actually participated in the study. It was conducted by 1000 primary and secondary care physicians.
In 31 patients a discrepancy between the diagnosis (type 1 diabetes) and administered treatment (oral antidiabetic drugs) was found. This group was classified as "unconfirmed diagnosis" and was excluded from further efficacy and safety analysis.
Assessments and outcome measures Data were collected from medical records, patient reports and diaries at baseline (first visit) and during the final visit after a 13-week follow-up. Physicians recorded the following information: demographics, medical history (type and duration of diabetes, micro-and macrovascular complications, the number of minor daytime and nocturnal hypoglycemic events during 4 weeks prior to the study, the number of all major daytime and nocturnal hypoglycemic events during the study), and measures of glycemic control: HbA 1c , fasting blood glucose (FBG), postprandial blood glucose (PPBG).
The primary endpoint was the incidence rate of major hypoglycemic events reported as serious adverse drug reactions during a 13-week treatment.
The secondary outcome measure during a 13-week treatment was safety: the number of all major (daytime and nocturnal) hypoglycemic events reported as serious adverse drug reactions, the number of all minor (daytime and nocturnal) hypoglycemic events during 4 weeks preceding the study, and changes in the body mass index (BMI) at the end of the study.
Another secondary outcome measure during a 13-week treatment was effectiveness: changes in HbA 1c at the end of the study, the proportion of patients who reached target HbA 1c ≤6.5% and <7% as well as the targets set by physicians, mean FBG and PPBG after main meals.
Major hypoglycemia was defined as an episode with severe central nervous system symptoms consistent with hypoglycemia that could not be self-treated by a patient and was associated with either a confirmed blood glucose reading <56 mg/dl (3.1 mmol/l) or prompt recovery after glucagon or intravenous glucose administration. Minor hypoglycemia was defined as setting because it is different from representative samples observed so far under optimal conditions in many RCTs. 34 Data from a 13-week follow-up of type 1 and 2 diabetic patients, treated with basal-bolus regimen of insulin aspart as mealtime insulin and either insulin detemir or NPH insulin as a basal component, showed low incidence of major hypoglycemic events. This was especially true for patients with type 2 diabetes. Apart from a marked improvement in glycemic control parameters, the results showed that intensive regimen with multiple insulin-aspart injections may be an efficient and safe option for treatment intensification in patients with type 2 diabetes. Compared with baseline, there was a significant reduction in the incidence of total daytime and nocturnal major hypoglycemic events. Our results are consistent with those obtained in clinical trials that showed improvement in glycemic control and a low risk of hypoglycemia, although it must be stressed that because it was an observational study, the recording and efficiency data were based on patient reports and diaries. 21, 27, [35] [36] conclusions Our results indicate that in patients with types 1 and 2 diabetes, introduction of insulin aspart as part of basal-bolus regimen leads to a clinically significant decrease in the number of hypoglycemic events along an improvement in blood glucose control. We proved that the beneficial results observed in clinical trials can also be achieved in routine clinical practice.
FBG and PPBG measured after all main meals (tAbLE 4).
At the end of follow-up, 9.8% of patients reached the target HbA 1c ≤6.5%, 31.4% reached the target HbA 1c <7%, and 14.8% reached the target set by individual physicians (tAbLE 4). When patients were analyzed according to diabetes type, similar effects were observed for basically all parameters, except that more patients with type 1 diabetes reached target HbA 1c targets of 6.5% and 7% compared with patients with type 2 diabetes (tAbLE 5). rationale for starting basal-bolus treatment with aspart as the bolus insulin The reasons for changing previous therapy to basal-bolus therapy with insulin aspart are presented in tAbLE 6. The main reason for the change was glycemic control (mainly postprandial but a substantial number of physicians also indicated fasting glucose and HbA 1c ).
dIscussIon All patients with type 1 and many patients with type 2 diabetes require intensive insulin therapy to achieve HbA 1c treatment goals. In diabetes management, it is important to maintain the balance between optimal glycemic control and hypoglycemia caused by too intensive glucose-lowering treatment. Hypoglycemia is the main barrier in initiating and continuing insulin therapy, and, according to recent data, it is associated with poorer clinical outcomes. 19 Our primary objective was to assess the incidence rates of severe hypoglycemic events in a large population-based cohort in everyday Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic con-26 trol with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998; 21: 1904 -1909 
